Drug Discovery Collaborations with Universities, Research Institutions and Biotech Ventures

「In March this year, we entered into a drug discovery collaboration agreement with Canada's Congruence Therapeutics to create new small-molecule compounds in the neurology and immunology areas.」

「In April last year, the company entered into a drug discovery partnership agreement with PRISM BioLab, Inc. to create drug candidates for cancer. In August last year, it entered into a research partnership agreement with Australia-based Monash University, including option rights, to create novel anti-GPCR antibodies for autoimmune and inflammatory diseases. In December last year, it entered into a drug discovery partnership agreement with Canada-based Congruence Therapeutics to create novel small-molecule compounds for cancer. In December last year, it began a research partnership with US-based Jorna Therapeutics concerning drug creation using RNA editing technology. In March this year, it entered into a drug discovery partnership agreement with Riborna Biosciences, Inc. to create RNA-targeted small-molecule drugs in the central nervous system field.」

「In April this year, the company entered into a drug discovery partnership agreement with PRISM BioLab, Inc. to create drug candidates for cancer. In August this year, it entered into a research partnership agreement with Australia-based Monash University, including option rights, to create novel anti-GPCR antibodies for autoimmune and inflammatory diseases.」

「In August last year, the company entered into a drug discovery partnership agreement with US-based Twist Bioscience to create antibody drugs for autoimmune diseases using its proprietary antibody library. In September last year, it entered into a drug discovery partnership agreement with US-based Adimab to create drug candidates for bispecific antibodies in the field of cancer using its antibody generation and engineering technology for therapeutic drugs. In October this year, it entered into a research partnership agreement with UK-based Turbine to identify and validate novel therapeutic targets in cancer using its AI-driven cell simulation platform.」

「The company began a Phase I trial in the United States of the iPS cell-derived HER2 CAR-T cell therapy ONO-8250 for HER2-positive solid tumors.」

「In August this year, the company entered into a drug discovery partnership agreement with US-based Twist Bioscience to create antibody drugs for autoimmune diseases using its proprietary antibody library. In September this year, it entered into a drug discovery partnership agreement with US-based Adimab to create drug candidates for bispecific antibodies in the field of cancer using its antibody generation and engineering technology for therapeutic drugs. In October this year, it entered into a research partnership agreement with UK-based Turbine to identify and validate novel therapeutic targets in cancer using its AI-driven cell simulation platform.」

「In November last year, the company entered into a drug discovery partnership agreement with Swiss-based Memo Therapeutics to create antibody drugs in the field of cancer immunology. In November last year, it entered into a drug discovery partnership agreement with Poland-based Captor Therapeutics to create targeted protein degradation small-molecule drugs against novel targets in the field of neurodegenerative diseases. In March this year, it entered into a drug discovery partnership agreement aimed at creating innovative antibody drugs against multiple targets using the AI drug discovery platform technology of MOLCURE, Inc.」

「In April this year, the company entered into a drug discovery partnership agreement with France-based Domain Therapeutics and the University of Montréal to create novel small-molecule compounds targeting GPCRs selected by the company in the field of metabolic diseases, applying their proprietary G protein-coupled receptor (GPCR) drug discovery platform and expertise in medicinal chemistry and pharmacology for GPCR drug discovery. In June this year, the company expanded its drug discovery partnership with US-based Fate Therapeutics, originally entered into in September 2018 to create iPS cell-derived chimeric antigen receptor (CAR)-T cell therapies, by entering into an agreement that also covers the creation of iPS cell-derived CAR-NK cell therapies. In August this year, the company entered into an agreement with Knowledge Palette to expand joint research aimed at building a data-driven new drug discovery platform using Knowledge Palette’s large-scale transcriptome analysis technology.」

「In August last year, the company entered into a research partnership agreement with UK-based Healx to create innovative therapies addressing unmet medical needs using the company’s proprietary artificial intelligence technology. In August last year, it entered into a drug discovery partnership agreement with Mirai Biologics to create next-generation biopharmaceuticals using LassoGraft Technology®, a new technology combining the company’s proprietary cyclic peptide discovery method with protein engineering. In January this year, it entered into a drug discovery partnership agreement with Swiss-based Neurimmune to create antibody drugs targeting drug discovery targets in neurodegenerative diseases using its proprietary antibody-generation approach, Reverse Translational MedicineTM technology. In March this year, it entered into a drug discovery partnership agreement with French-based Iktos to create innovative small-molecule compounds against drug discovery targets presented by the company using Iktos’s proprietary artificial intelligence (AI) drug discovery technology for designing novel chemical structures. In March this year, the company exercised its option under the agreement concerning the creation of multispecific antibodies in the field of cancer immunology that it had entered into with Swiss-based Numab in 2017, and entered into a new development and license agreement.」

「In August this year, the company entered into a research partnership agreement with UK-based Healx to create innovative therapies addressing unmet medical needs using the company’s proprietary artificial intelligence technology. In August this year, it entered into a drug discovery partnership agreement with Mirai Biologics to create next-generation biopharmaceuticals using LassoGraft Technology®, a new technology combining the company’s proprietary cyclic peptide discovery method with protein engineering.」

「In March this year, the company entered into a non-exclusive license agreement with PeptiDream Inc. concerning the automation platform of its proprietary drug discovery development platform system, the Peptide Discovery Platform System. In March this year, it joined the University of California’s drug discovery consortium to approach early-stage research programs at 7 member universities and efficiently promote drug discovery research based on innovative drug discovery ideas from the 7 member universities.」

「In March this year, the company entered into a new drug discovery partnership agreement and option agreement with Swiss-based Numab to create multispecific antibodies in the field of cancer immunology.」

「In March this year, the company entered into a research partnership agreement with US-based Tzuri to create innovative therapies addressing unmet needs in neurological diseases using the company’s proprietary artificial intelligence (AI) technology. In March this year, it entered into a strategic drug discovery partnership agreement with Cancer Research UK and LifeArc in the field of cancer immunology. In March this year, it entered into a drug discovery partnership agreement with French-based Vectura to create drug candidates for neurodegenerative diseases.」

「In May this year, the company established the Immuno-Inflammatory Intractable Disease Drug Discovery Consortium with Keio University, Kochi University, the National Institutes of Biomedical Innovation, Health and Nutrition, Mitsubishi Tanabe Pharma Corporation and DAIICHI SANKYO COMPANY,LIMITED to conduct drug discovery research targeting immuno-inflammatory intractable diseases. In September this year, it entered into a drug discovery partnership agreement with US-based Fate Therapeutics to create an allogeneic CAR-T cell therapy derived from iPS cells for cancer.」

「In November last year, the company entered into a drug discovery partnership agreement with Swiss-based Neurimmune to create antibody drugs targeting novel drug discovery targets in the field of neurodegenerative diseases. In December last year, it entered into a partnership agreement with Canadian-based Cyclica to pursue drug discovery using the company’s proprietary next-generation medium-sized molecule drug discovery technology. In December last year, it entered into a partnership agreement with US-based Schrödinger to pursue drug discovery using the company’s proprietary computer-aided drug discovery technology. In March this year, it entered into a drug discovery partnership agreement with Dutch-based Merus to create bispecific antibodies against drug discovery targets selected by the company in the field of autoimmune diseases.」

「The company conducts joint research with universities and research institutions engaged in cutting-edge research worldwide to explore new drug discovery seeds that could lead to breakthrough new drugs. By combining the drug discovery expertise it has developed through its research activities with the cutting-edge technologies of biotech ventures, it aims to create drug candidates for diseases with high unmet medical needs. During the period, it newly initiated 49 joint research projects and research partnerships with universities, research institutions and biotech ventures in Japan and overseas.」

「During the period, the company newly initiated 125 joint research projects and research partnerships with universities, research institutions and biotech ventures in Japan and overseas. / In September last year, the company entered into a comprehensive research partnership agreement with the National Cancer Center Japan, an incorporated National Research and Development Agency, to promote joint research aimed at creating superior anticancer drugs and discovering biomarkers for cancer immunotherapy and other applications by leveraging the research capabilities of both parties.」

「The company conducts joint research with universities and research institutions engaged in cutting-edge research worldwide to explore new drug discovery seeds that could lead to breakthrough new drugs. By combining the drug discovery expertise it has developed through its research activities with the cutting-edge technologies of biotech ventures, it aims to create drug candidates for diseases with high unmet medical needs. During the period, it newly initiated 70 joint research projects and research partnerships with universities, research institutions and biotech ventures in Japan and overseas. / In September this year, the company entered into a comprehensive research partnership agreement with the National Cancer Center Japan, an incorporated National Research and Development Agency, to promote joint research aimed at creating superior anticancer drugs and discovering biomarkers for cancer immunotherapy and other applications by leveraging the research capabilities of both parties. It also launched a large-scale joint research project with the same institution to comprehensively analyze systemic and local tumor immune status in cancer patients, as well as tumor genetic mutations and expression across cancer types and the metabolic states of tumors and immune cells.」

「We will actively pursue open innovation with research institutions, universities and venture companies that possess world-leading knowledge and technologies, thereby improving the efficiency of drug discovery research and increasing the probability of success in creating new drugs. / During the fiscal year, we newly began 93 joint research projects and research collaborations with universities, research institutions and biotechnology ventures in Japan and overseas.」